Printer Friendly

Synthego adds new member to advisory board.

M2 PHARMA-September 22, 2017-Synthego adds new member to advisory board

(C)2017 M2 COMMUNICATIONS

Synthego, a US-based Genome engineering solutions provider, has added Sir Andrew Witty to its advisory board, it is reported today.

In the new role, Witty will work on biological research and grow the company's application development and bioinformatics expertise.

Witty has previously served on the board of directors at GlaxoSmithKline, where he was chief executive officer from 2008 - 2017. He has more than 30 years' experience and his biopharma expertise ranges from product management and business development, to strategic partnerships.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 22, 2017
Words:105
Previous Article:Alligator Bioscience announces presentation of ADC-1013 intratumoural clinical phase I study results at SITC in November 2017.
Next Article:Shady Grove Fertility Simplifies Egg Donation, Donor Selection with New Portal.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters